Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
Body unavailable. Use the original source.
Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.